Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Sponsor: Walter Reed National Military Medical Center
Summary
A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.
Official title: Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
152
Start Date
2022-10-01
Completion Date
2027-01-30
Last Updated
2024-08-19
Healthy Volunteers
Yes
Conditions
Interventions
Vaginal estrogen
0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
Mirabegron 50 MG [Myrbetriq]
50mg oral Mirabegron once daily
Locations (1)
Walter Reed National Military Medical Center
Bethesda, Maryland, United States